Intravitreal ranibizumab therapy in wet type macular degeneration Yaş tip maküla dejenerasyonunda İntravitreal ranibizumab tedavisi


Dündar H., ALTINKAYNAK H., Kocasaraç C., Hazar L., Yüksel K., Yazıcı A. T.

Turk Oftalmoloiji Dergisi, cilt.44, sa.5, ss.356-360, 2014 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 5
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4274/tjo.02418
  • Dergi Adı: Turk Oftalmoloiji Dergisi
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.356-360
  • Anahtar Kelimeler: Fluorescein angiography, optical coherence tomography, ranibizumab, age-related macular degeneration
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Conclusion: Intravitreal ranibizumab treatment is efficient and safe in all types of choroidal neovascularization that develops secondary to age-related macular degeneration. Flexible dosing interval increases the patient compliance and anatomical and functional success rate. Objectives: To evaluate the efficacy and safety of intravitreal ranibizumab treatment in all types of choroidal neovascularization that developed secondary to age-related macular degeneration. Materials and Methods: We enrolled ninety-four eyes of 92 patients with previously untreated neovascular age-related macular degeneration who underwent intravitreal ranibizumab injection and were followed for at least 12 months. All of the patients underwent a complete examination, including best-corrected visual acuity (BCVA) (Snellen), biomicroscopy, and dilated fundus examination at preoperatively and postoperative follow-up visits. Number of injections and frequency of follow-up visits per year were evaluated. Size, location, and type of the lesions were evaluated by fuorescein angiography (FA). Pre- and postoperative changes in lesion size, central macular and foveal thickness measured by OCT were compared. Results: A total of 92 patients (36 women and 56 men) with a mean age of 69.1±11.0 years were evaluated. Mean follow-up time was 14.6±3.44 (12-25) months, and mean number of injections was 4.9±1.81 (3-12). The average annual number of follow-up visits wasc 9.2±1.02 (8-12). Patients’ mean best-corrected visual acuity increased by 12.1 letters. The lesion size was 3.27±0.95 µm at pre-treatment period and improved to 2.72±1.15 µm in post-treatment period measured by FA (p=0.006). Leakage was still detected in ten patients at final follow-up visit. Statistically significant decrease in macular and foveal thickness was recorded in all post-treatment measurements compared to pre-treatment ones.